Key Publications


Nilotinib as frontline and second-line therapy in chronic myeloid leukemia: Open questions. Valent P, Gastl G, Geissler K, Greil R, Hantschel O, Lang A, Linkesch W, Lion T, Petzer AL, Pittermann E, Pleyer L, Thaler J, Wolf D. Crit Rev Oncol Hematol. 2011 Sep 6. [Epub ahead of print] PMID: 21903413


First annual report of the Austrian CML registry. Schmidt S, Wolf D, Thaler J, Burgstaller S, Linkesch W, Petzer A, Fridrik M, Lang A, Agis H, Valent P, Krieger O, Walder A, Korger M, Schlögl E, Sliwa T, Wöll E, Mitterer M, Eisterer W, Pober M, Gastl G; ASHO CML registry. Wien Klin Wochenschr. 2010 Oct;122(19-20):558-66. Epub 2010 Oct 11. PMID: 20936366


High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 "ISTAHIT" study. Petzer AL, Wolf D, Fong D, Lion T, Dyagil I, Masliak Z, Bogdanovic A, Griskevicius L, Lejniece S, Goranov S, Gercheva L, Stojanovic A, Peytchev D, Tzvetkov N, Griniute R, Oucheva R, Ulmer H, Kwakkelstein M, Rancati F, Gastl G. Haematologica. 2010 Jun;95(6):908-13. Epub 2010 Feb 9. PMID: 20145273


A benefit-risk assessment of imatinib in chronic myeloid leukaemia and gastrointestinal stromal tumours. Wolf D, Rumpold H. Drug Saf. 2009;32(11):1001-15. doi: 10.2165/11314600-000000000-00000. Review. PMID: 19810774


Role of gene-expression profiling in chronic myeloid leukemia. Schmidt S, Wolf D. Expert Rev Hematol. 2009 Feb;2(1):93-103. Review. PMID: 21082998


Diagnostic algorithms, monitoring, prognostication, and therapy in chronic myeloid leukemia (CML): a proposal of the Austrian CML platform. Valent P, Lion T, Wolf D, Sillaber C, Agis H, Petzer A, Lang A, Kalhs P, Geissler D, Greil R, Linkesch W, Burgstaller S, Thaler J, Gastl G. Wien Klin Wochenschr. 2008;120(21-22):697-709. PMID: 19116712

Possible role for gene expression profiling in predicting responses to conventional or targeted drugs in patients with chronic myeloid leukemia. Schmidt S, Gastl G, Wolf D. Leuk Lymphoma. 2008 Apr;49(4):643-7. Review. PMID: 18398726


The kinase inhibitor imatinib--an immunosuppressive drug? Wolf D, Tilg H, Rumpold H, Gastl G, Wolf AM. Curr Cancer Drug Targets. 2007 May;7(3):251-8. Review. PMID: 17504122


Anti-leukemic activity of valproic acid and imatinib mesylate on human Ph+ ALL and CML cells in vitro. Kircher B, Schumacher P, Petzer A, Hoflehner E, Haun M, Wolf AM, Nachbaur D, Gastl G. Eur J Haematol. 2009 Jul;83(1):48-56. Epub 2009 Feb 17. PMID: 19226363